comparemela.com

Page 4 - Vinod Thourani News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The biggest cardiovascular stories from TCT 2023

Every year, some of the biggest names in cardiovascular technologies come together in one place for the TCT conference.

San franciscoUnited statesVinod thouraniLarry woodMichael reardonAbbott triclipPhilipd rackliffeBoston scientificGe healthcareNational swedeheart quality registryTranscatheter cardiovascular therapeuticsNew hampshire based conformal medicalInteract touchTrilogy transcatheter heart valveMedtronic intrepid

Trilogy TAVR Safe, Effective in Aortic Regurgitation

The Trilogy transcatheter aortic valve replacement system was safe and effective for high-risk surgical patients with aortic regurgitation, improving LV remodeling and function, in the ALIGN-AR trial.

United statesRobert bonowVinod thouraniNorthwestern university feinberg school of medicineJenavalve technologyPiedmont heart institute in atlantaDrug administrationJenavalve trilogyPiedmont heart instituteTranscatheter cardiovascular therapeuticsNorthwestern university feinberg schoolAortic insufficiencyImplanted device cardiologyTranscatheter aortic valve replacement tavrRanscatheter aortic valve implantation taviPercutaneous aortic valve replacement

Early Experience Keeps Tendyne TMVR on Track for MR and Severe MAC

Will preliminary results be confirmed by SUMMIT trial to come?

Jason rogersNicole louVinod thouraniLos angelesJoanna chikweYork heart associationSinai medical centerPiedmont heart institute in atlantaUc davis medical centerCardiovascular research foundationMedical centerTranscatheter cardiovascular therapeuticsCardiovascular researchPiedmont heart instituteCedars sinai medical centerNew york heart association

JenaValve TCT highlights: Aiming to tackle aortic regurgitation

JenaValve's approach to transcatheter aortic valve replacement (TAVR) was highlighted at the 2023 TCT conference.

Markus ferrariVinod thouraniHans figullaFriedrich schiller universityTranscatheter cardiovascular therapeuticsFriedrich schillerTrilogy transcatheter heart valve

JenaValve Announces Late-Breaking Data from the ALIGN-AR Pivotal Trial Meeting Safety and Efficacy Endpoints

IRVINE, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Val.

United kingdomUnited statesSan franciscoRaj makkarTorstenp vahlMarissa bychDuane pintoBain capital life sciencesVinod thourani piedmont heart institutePeijia medicalCompany trilogyQatar investment authorityValiance life sciencesJenavalve technology incDrug administrationValve technology

vimarsana © 2020. All Rights Reserved.